SCHEMBL10278329

SCHEMBL10278329

CC(C)(NCCCS(=O)(=O)O)C(O)c1ccccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 3/20 0.45
ADRB1 P08588 3/20 0.45
CYP2D6 P10635 2/20 0.45
NFKB1 P19838 1/20 0.45
HIF1A Q16665 1/20 0.45
BLM P54132 1/20 0.44
AOC3 Q16853 1/20 0.34
CASR P41180 1/20 0.33
CXCL8 P10145 1/20 0.33
ADRB3 P13945 1/20 0.33
CASP1 P29466 1/20 0.33
CYP3A4 P08684 2/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
CDC25A P30304 2/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
GLS O94925 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10278328 0.87 HDAC1 (0.34) ADRB2ADRB1CYP2D6NFKB1HIF1A
SCHEMBL10278389 0.85 ADRB2 (0.40) ADRB2ADRB1CYP2D6NFKB1HIF1A
SCHEMBL10278316 0.85 ADRB2 (0.33) ADRB2ADRB1ADRB3CYP3A4LMNA
SCHEMBL10278386 0.85 CYP2D6 (0.31) ADRB2ADRB1CYP2D6NFKB1HIF1A
SCHEMBL10278410 0.85 HTT (0.37) ADRB2ADRB1CYP2D6NFKB1HIF1A
SCHEMBL10278385 0.84 ACHE (0.38) CYP2D6CYP3A4HTTTP53TSHR
SCHEMBL10278360 0.82 CNR2 (0.36) ADRB2ADRB1CYP2D6CYP3A4SLC6A4
SCHEMBL10278313 0.81 TMEM97 (0.39) ADRB2AOC3ADRB3LMNAMAPT
SCHEMBL10278358 0.79 GABBR2 (0.38) CYP3A4SLC6A3MEN1CYP1A2TSHR
SCHEMBL10278346 0.79 ADRB3 (0.38) ADRB2ADRB1CASRADRB3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2014-11-06 US disclosed
US-8835654-B2 Method and compositions for treating amyloid-related diseases BHI LIMITED PARTNERSHIP (CA) 2014-09-16 US disclosed
US-20140107027-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES BHI LIMITED PARTNERSHIP (CA) 2014-04-17 US disclosed
US-8642801-B2 Methods and compositions for treating amyloid-related diseases BHI LIMITED PARTNERSHIP (CA) 2014-02-04 US disclosed
US-20120015911-A1 METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES BELLUS HEALTH INC. (CA) 2012-01-19 US disclosed
US-8044100-B2 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH INC. (CA) 2011-10-25 US disclosed
US-8044100-B2 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH INC. (CA) 2011-10-25 US disclosed
US-20100113591-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2010-05-06 US disclosed
US-20100113591-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2010-05-06 US disclosed
US-7414076-B2 Methods and compositions for treating amyloid-related diseases NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2008-08-19 US disclosed
US-7414076-B2 Methods and compositions for treating amyloid-related diseases NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2008-08-19 US disclosed
US-20070010573-A1 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2007-01-11 US disclosed
US-20070010573-A1 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 ADRB2 1298/4885ADRB1 1012/4885CYP2D6 3675/4885
US-20140107027-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 ADRB2 1298/4885ADRB1 1012/4885CYP2D6 3675/4885
US-20100113591-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 ADRB2 1298/4885ADRB1 1012/4885CYP2D6 3675/4885
US-20120015911-A1 METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 ADRB2 1049/4885ADRB1 695/4885CYP2D6 2897/4885
US-20070010573-A1 Methods and compositions for treating amyloid-related diseases APP, PSEN1, PSEN2 ADRB2 1298/4885ADRB1 1012/4885CYP2D6 3675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.